Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

被引:1
作者
Echeverri, Jorge [1 ]
Martins, Rui [2 ,3 ,4 ]
Harenski, Kai [5 ]
Kampf, J. Patrick [6 ]
Mcpherson, Paul [6 ]
Textoris, Julien [7 ,8 ,9 ,10 ]
Koyner, Jay L. [11 ]
机构
[1] Baxter Healthcare Corp, Global Med Affairs, Deerfield, IL USA
[2] Univ Groningen, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands
[3] Hlth Econ, St Prex, Switzerland
[4] Global Market Access Solut, St Prex, Switzerland
[5] Baxter Deutschland GmbH, Global Med Affairs, Unterschleissheim, Germany
[6] Astute Med Inc, Biomarker Res, San Diego, CA USA
[7] Med Affairs, Lyon, France
[8] bioMerieux SA, Lyon, France
[9] Serv Anesthesie & Reanimat, Lyon, France
[10] Hosp Civils Lyon, Lyon, France
[11] Univ Chicago, Dept Med, Sect Nephrol, Chicago, IL USA
来源
CLINICOECONOMICS AND OUTCOMES RESEARCH | 2024年 / 16卷
关键词
acute kidney injury; dialysis; biomarkers; nephrology; cost effectiveness; OUTCOMES; AKI;
D O I
10.2147/CEOR.S434971
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Approximately 24% of hospitalized stage 2- 3 acute kidney injury (AKI) patients will develop persistent severe AKI (PS-AKI), defined as KDIGO stage 3 AKI lasting >= 3 days or with death in <= 3 days or stage 2 or 3 AKI with dialysis in <= 3 days, leading to worse outcomes and higher costs. There is currently no consensus on an intervention that effectively reverts the course of AKI and prevents PS-AKI in the population with stage 2- 3 AKI. This study explores the cost-utility of biomarkers predicting PS-AKI, under the assumption that such intervention exists by comparing C-C motif chemokine ligand 14 (CCL14) to hospital standard of care (SOC) alone.<br />Methods: The analysis combined a 90-day decision tree using CCL14 operating characteristics to predict PS-AKI and clinical outcomes in 66-year-old patients, and a Markov cohort estimating lifetime costs and quality-adjusted life years (QALYs). Cost and QALYs from admission, 30-day readmission, intensive care, dialysis, and death were compared. Clinical and cost inputs were informed by a large retrospective cohort of US hospitals in the PINC AI Healthcare Database. Inputs and assumptions were challenged in deterministic and probabilistic sensitivity analyses. Two-way analyses were used to explore the efficacy and costs of an intervention preventing PS-AKI.<br />Results: Depending on selected costs and early intervention efficacy, CCL14-directed care led to lower costs and more QALYs (dominating) or was cost-effective at the $50,000/QALY threshold. Assuming the intervention would avoid 10% of PS-AKI complications in AKI stage 2- 3 patients identified as true positive resulted in 0.066 additional QALYs and $486 reduced costs. Results were robust to substantial parameter variation.<br />Conclusion: The analysis suggests that in the presence of an efficacious intervention preventing PS-AKI, identifying people at risk using CCL14 in addition to SOC is likely to represent a cost-effective use of resources.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 29 条
  • [1] [Anonymous], 2006, DECISION MODELLING H
  • [2] [Anonymous], 2022, MICROSOFT EXCEL MICR
  • [3] [Anonymous], 2022, Healthcare Cost and Utilization Project (HCUP)
  • [4] Arias Elizabeth, 2019, Natl Vital Stat Rep, V68, P1
  • [5] Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
    Brazzelli, Miriam
    Aucott, Lorna
    Aceves-Martins, Magaly
    Robertson, Clare
    Jacobsen, Elisabet
    Imamura, Mari
    Poobalan, Amudha
    Manson, Paul
    Scotland, Graham
    Kaye, Callum
    Sawhney, Simon
    Boyers, Dwayne
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2022, 26 (07) : 1 - 285
  • [6] ClinicalTrials.gov, Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery (PrevProgAKI)-NCT05275218
  • [7] CMS, Calendar Year 2023 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-1768-F)
  • [8] The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation
    Hall, Peter S.
    Mitchell, Elizabeth D.
    Smith, Alison F.
    Cairns, David A.
    Messenger, Michael
    Hutchinson, Michelle
    Wright, Judy
    Vinall-Collier, Karen
    Corps, Claire
    Hamilton, Patrick
    Meads, David
    Lewington, Andrew
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2018, 22 (32) : 1 - +
  • [9] Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
    Hoste, Eric
    Bihorac, Azra
    Al-Khafaji, Ali
    Ortega, Luis M.
    Ostermann, Marlies
    Haase, Michael
    Zacharowski, Kai
    Wunderink, Richard
    Heung, Michael
    Lissauer, Matthew
    Self, Wesley H.
    Koyner, Jay L.
    Honore, Patrick M.
    Prowle, John R.
    Joannidis, Michael
    Forni, Lui G.
    Kampf, J. Patrick
    McPherson, Paul
    Kellum, John A.
    Chawla, Lakhmir S.
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (05) : 943 - 953
  • [10] ICER, 2020-2023 value assessment framework 2020